Volume 12, Issue 2, June 2008
     
Genetics and Health Care
A Tidal Wave of New Information

Jennifer T. Loud, RN, MSN, CRNP, DNP
Derwood, MD
loudj@mail.nih.gov


A recent article in The New York Times reinforced the importance of keeping up with new information on genetics and genomics. In this fascinating article (April 13, 2008), Patrick McGeehan wrote about a company that recently began selling genetic scans directly to consumers. In a showroom in SoHo, a company advertised that for $2,500 it could use a saliva sample to analyze a person’s DNA to predict his or her risk of contracting 1 of 18 conditions, including breast cancer, a heart attack, and Alzheimer’s disease. In addition, the company offered to provide updates based on the latest findings on those and other illnesses for an extra $250 per year. How long will it be until patients bring these results to their annual check-ups and ask their healthcare providers to interpret the results?

Janssens et al. (2008), reported that seven companies currently offer genomic profiles directly to consumers. They also concluded that insufficient evidence exists indicating that genomic profiles are useful for measuring genetic risk for common diseases or for developing personalized recommendations for diet or lifestyle modifications intended to reduce the risk of developing a disease. The American College of Medical Genetics recently published a policy statement on direct-to-consumer genetic testing, which is intended as an educational resource for all healthcare clinicians. You may view the policy statement here.

ONS and the Cancer Genetics (CAG) SIG support the Essential Nursing Competencies and Curriculum Guidelines for Genetics and Genomics. The CAG SIG’s members look for opportunities to advance the educational and professional development of all oncology nurses in their efforts to maintain excellence in the field of cancer genetics and genomics. As one of the endorsing organizations of the essential nursing competencies, ONS remains the premier professional organization to support educational opportunities for oncology nurses.

This newsletter will reach you after Congress 2008, and I hope that we had a chance to visit, catch up, and set next years’ priorities for the CAG SIG. Lisa Aiello-Laws, RN, MSN, APN-C, APNG, AOCNS®, as the new SIG coordinator, brings an exemplary professional background to the position, as well as new energy and enthusiasm for all things genetic. As of March 2008, our membership has grown to 385 members and the need persists for ongoing support of oncology nurses’ educational and professional development in cancer genetics. We welcome our members’ input regarding specific educational priorities for the CAG SIG. Whether you are looking for specific presentations at ONS meetings, would like to write an article, or would like to review an article for the newsletter, your participation in the CAG SIG is welcome and strongly encouraged. We are specifically looking for someone who is interested in online communication via the Virtual Community to help us develop that communication tool more fully. You may e-mail the leadership team directly or place a message on the Virtual Community.

Reference

Janssens, A.C., Gwinn, M., Bradley, L.A., Oostra, B.A., van Duijn, C.M., & Khoury, M.J. (2008). A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. American Journal of Human Genetics, 82(3), 593-599.

 
The Cancer Genetics SIG Newsletter is produced by members of the
Cancer Genetics SIG and ONS staff and is not a peer-reviewed publication.

Special Interest Group Newsletter  June 2008
 
   

New Coordinator's Message

Lisa Aiello-Laws, RN, MSN, APN-C, APNG, AOCNS®
Philadelphia, PA
llaws@itapartners.com


First, I would like to thank Jennifer Loud for serving as coordinator of the Cancer Genetics (CAG) SIG. She has shared her wealth of knowledge as well as mentored members as they developed their genetic expertise. And, during all of this, she obtained her DNP! Congratulations, Jen!

I am excited to serve as the new coordinator of the CAG SIG. I have many ideas for the goals of our SIG, such as increasing membership, providing education about nursing genetic competencies, increasing genetic presentations at Congress, and increasing genetic content in ONCC exams. However, I want to hear from you! Because you are receiving this newsletter after Congress, I am sure we had a productive SIG meeting with a sharing of ideas and networking. I will summarize the meeting for you after Congress. Please remember that even if you have joined the SIG, you still have to sign up on the Virtual Community for email updates. On the main page, sign up for email announcements. You also can subscribe to the calendar page and the discussion page. This will provide you with email notification of new postings.

I also would like to reiterate Jen’s comments and invite you to take a more active role in our SIG. Everyone is welcome, regardless of genetic expertise or nursing degree.

I look forward to serving and working with you to improve genetic knowledge and networking within ONS.
 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

Genetics Reference Articles

Millie Arnold, BS, RN, OCN®, CCRC
Dallas, TX
mildreda@baylorhealth.edu

Patricia Kelly, RN, MS, CNS, AOCN®
Dallas, TX
patriciakelly@texashealth.org


The following are specific newsworthy research articles of interest. If you or other members of the Cancer Genetics (CAG) SIG have recently published, please send the CAG SIG Leadership Team notification of the publication. We would like to list members’ publications in the CAG SIG Newsletter to draw attention to the professional accomplishments of our members.

Feero, W.G., Guttmacher, A.E., & Collins, F.S. (2008). The genome gets personal—almost. JAMA, 299(11), 1351-1352.

Hadley, D.W., Jenkins, J.F., Steinberg, S.M., Liewehr, D., Moller, S., Martin, J.C., et al. (2008). Perceptions of cancer risks and predictors of colon and endometrial cancer screening in women undergoing genetic testing for Lynch syndrome. Journal of Clinical Oncology, 26(6), 948-954.

Kelly, P. (2008). Understanding genomics: No longer optional for gastroenterology nurses. Gastroenterology Nursing, 31(1), 45-54.

Offit, K. (2008). Genomic profiles for disease risk. JAMA, 299(11), 1353-1355.

Scheuner, M.T., Sieverding, P., & Shekelle, P.G. (2008). Delivery of genomic medicine for common chronic adult diseases: A systematic review. JAMA, 299(11), 1320-1334. 

The complete March 19th issue of the Journal of the American Medical Association (JAMA) focused on genetics and genomics.

 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

Completing a Genetic History: Identifying the Family at Risk

Presented at the 33rd Annual ONS Congress
Saturday, May 17, 2008
Jennifer T. Loud, RN, MSN, CRNP, DNP
Derwood, MD
loudj@mail.nih.gov

Millie Arnold, BS, RN, OCN®, CCRC
Dallas, TX
mildreda@baylorhealth.edu

Marty Weinar, RN, MS, CCRC
Philadelphia, PA 
marty.weinar@ctca-hope.com

The rapidly changing field of genetics and genomics impacts all professional healthcare disciplines and uniquely impacts oncology nurses. Regardless of the oncology nursing sub-specialty, oncology nurses frequently have the opportunity to identify high-risk individuals and families and integrate family health history into daily practice. The instructional session included

  • An overview of genetics
  • A review of the characteristics of hereditary family syndromes
  • Instructions to obtain a family history
  • The opportunity to develop a cancer genetic family pedigree.

Although most cancers are sporadic in origin, identifying high-risk families is an important first step in cancer screening and prevention. Obtaining a thorough and accurate family history, including at least three generations, is a cost-effective, vital tool for establishing cancer genetic risk in families. Participants in the instructional session were challenged to return with a plan of action for implementing a family history tool that can identify high-risk families. 

Attendees of this session not only received information but also were offered an opportunity for hands-on participation and provided tools to create their own three-generation pedigree. A thorough explanation of genetic terms, symbols, and interpretations of high-risk family pedigrees completed this informative ONS session.

Thanks to the new Cancer Genetics SIG coordinator, Lisa Aiello-Laws, RN, MSN, APN-C, APNG, AOCNS®, for submitting this topic for ONS Congress.
 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

News You Can Use From the National Cancer Institute
Newly Identified Genetic Variations May Affect Breast Cancer Risk

Jennifer T. Loud, RN, MSN, CRNP, DNP
Derwood, MD
Loudj@mail.nih.gov


Researchers have identified genetic variations in a region of DNA that may be associated with risk for breast cancer. Women with the variation have a 1.4 times greater risk of developing breast cancer compared to those without this variation. The study is one of several genome-wide association studies looking for breast cancer genes and to be published this year by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues. These findings appeared online in the Proceedings of the National Academy of Sciences on March 3, 2008.

"A genome-wide association study (GWAS) looks at the entire genome for a type of genetic variation that occurs more frequently in people who have a certain disease than in similar people who do not have the disease," said Bert Gold, PhD, of NCI's Center for Cancer Research and the study's lead author. "Using this research approach, we found variations in a gene locus, a specific place on a chromosome where a gene is located, that had not been identified in previous studies."

A GWAS looks for a genetic variation known as a single nucleotide polymorphism (SNP). SNPs are alterations in the genetic code in which a single nucleotide, the individual building block that makes up DNA, is changed. The researchers found that variations in four SNPs located in a region of chromosome 6 were present more often in the patients with breast cancer, suggesting that genes in this region might contribute to the risk of breast cancer. The researchers also confirmed the finding of previous studies indicating that the locus named FGFR2 is associated with a 20% increased risk of breast cancer.

"The likelihood that this finding could be due to chance alone is about one in 300 million," said Gold. "We have already begun experiments to try to identify the genes associated with risk and then try to characterize their function. It is hoped that identifying the genes responsible for this increased risk may lead to new therapies that target the actions of these genes."

"Progressing from genome-wide association studies to the development of therapies and enhanced diagnostic techniques based on those findings will require continued, sustained effort from laboratory researchers who will unite our newfound knowledge of the genome with the study of cancer biology," said NCI Director John E. Niederhuber, MD.

Several genes located in this chromosome region play a role in regulating important cell processes such as cell cycle, DNA replication and repair, cell signaling, and programmed cell death. Defects in these processes have been well documented in breast cancer. While the variations in chromosome 6 that increase risk for breast cancer were found in 23% of the women studied, their risk for developing breast cancer is relatively small compared to the high risk associated with BRCA gene mutations. BRCA genes were identified in the 1990s, and mutations in these genes are among the strongest known genetic risk factors for breast cancer. The researchers estimate that only about 7% of breast cancer cases in this current study could be attributed to the locus they found on chromosome 6.

"Although identifying individual low-risk loci may have limited clinical implications, it is not known whether interactions among multiple loci will put a woman at greater risk of developing breast cancer," said Gold. "A better understanding of the genetic mutations that contribute to breast cancer is likely to come from the identification of these low-risk variants and from studies that investigate the mechanisms underlying their associations."

The researchers conducted a three-phase GWAS to look for SNPs that may be associated with breast cancer risk. In the first phase, they analyzed more than 150,000 SNPs in DNA samples obtained from 249 Ashkenazi Jewish women who had breast cancer and a family history of the disease but did not carry the BRCA1 or BRCA2 mutation and from 299 Ashkenazi Jewish women who had not developed cancer. They studied Ashkenazi Jewish women because many studies have demonstrated that this population has been associated with an increased breast cancer risk compared to other populations. In the next two phases, the researchers verified their findings in 950 Ashkenazi Jewish women with breast cancer and 979 Ashkenazi Jewish women who did not have cancer as well as in a set of 243 Ashkenazi Jewish women who had sporadic breast cancer and 187 cancer-free Ashkenazi Jewish women. The study participants indicated that all four of their grandparents were Jewish and of Eastern European descent.

The study was designed and directed by a research team at Memorial Sloan-Kettering Cancer Center in New York, NY, with participation from other centers in the United States, Canada, and Israel. In addition to the study coordinating center at Memorial Sloan-Kettering, this study was a collaboration between NCI; researchers at Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Tel-Aviv University, Tel-Aviv, Israel; Centre for Research in Women's Health, Toronto, Canada; North Shore Long Island Jewish Research Institute, Manhasset, NY; SAIC-Frederick, Inc., Frederick, MD; University of Chicago, Chicago, IL; Cornell University, Ithaca, NY; and Memorial Health University Medical Center, Anderson Cancer Institute, Savannah, GA.

Reference

Gold, B., Kirchhoff, T., Stefanov, S., Lautenberger, J., Viale, A., Garber, J., et al. (2008). Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences, 105(11), 4340-4345.

 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

National Coalition for Health Professional Education in Genetics
A Genetics Education Resource

Patricia A. Kelly, RN, MS, CNS, AOCN®
ONS Representative to NCHPEG
Dallas, TX
patriciakelly@texashealth.org


Established in 1996 by the American Medical Association, the American Nurses Association, and the National Human Genome Institute, the National Coalition of Health Professional Education in Genetics (NCHPEG) (phonetically: netch-peg) is an "organization of organizations" committed to a national effort to promote health professional education and access to information about advances in human genetics (NCHPEG, 2003).

ONS is 1 of 141 NCHPEG health professional organizational members. Navigate the Web site and check out the genomics education resources including InPractice Newsletters and GROW (genetic resources on the web). Use these excellent materials when instituting the American Nurses Association’s (2006) Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics (American Nurses Association, 2006).

American Nurses Association. (2006). Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics. Retrieved April 15, 2008, from http://www.genome.gov/
Pages/Careers/HealthProfessionalEducation/geneticscompetency.pdf

National Coalition for Health Professional Education in Genetics. (2003). Mission and background. Retrieved April 15, 2008, from http://www.nchpeg.org/content.asp?dbsection=about

 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

President Bush Signs Genetic Information Nondiscrimination Act

Millie Arnold, RN, BS, OCN®, CCRC
Dallas, TX
mildreda@baylorhealth.edu
with written permission from GenomeWeb Daily News


On Wednesday, May 21, 2008, President Bush signed the long-awaited Genetic Information Nondiscrimination Act of 2008 (GINA) into law. 

GINA provides vital protection for Americans against the misuse of genetic test results by heath insurers and employers.

“Americans have been waiting a long time for this bill, but the wait has been worth it,” said Center Director Kathy Hudson. “Our challenge now is to make sure that doctors and patients are aware of these new protections so that fear of discrimination never again stands in the way of a decision to take a potentially life-saving genetic test.”

Until now, individuals’ genetic information has been protected only by a largely untested patchwork of state and federal regulations.  According to a poll conducted last year by the center, 92% of Americans were concerned that results of a genetic test could be used in ways that would be harmful to them. GINA’s passage should allay public fears of genetic discrimination, allowing individuals to take advantage of the genetic tests that are now clinically available for approximately 1,500 diseases.

GINA prevents health insurers from denying coverage, adjusting premiums on the basis of genetic information, or requesting that an individual undergo a genetic test. Similarly, employers are prohibited from using genetic information to make hiring, firing, or promotion decisions. The law also sharply limits an employer’s right to request, require, or purchase an employee’s genetic information.

The law helps reassure patients who could benefit from genetic testing but have forgone it out of concern over possible repercussions. When people opt not to be tested, they lose the opportunity to seek monitoring and preventive care. Passage of GINA means that Americans will no longer have to make trade-offs between genetic privacy and appropriate health care.

GINA will benefit genetic research as well as individuals. Linking gene variants to health outcomes often requires studies involving large numbers of people, but scientists report that potential subjects have been deterred by the fear that their information could be used against them by employers and insurers. Now, however, scientists will be able to assure study participants that neither their participation in a research study nor their genetic information can be legally used against them by their employers or health insurers.

Oncology nurses are encouraged to join ONStat to become better informed about patient-related legislative topics. As oncology nurses each of us must have an increased  awareness about state and federal legislative issues that affect healthcare services. Individual and collective involvement  strengthens our abilities to serve as patient advocates.
 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

Researchers Identify Novel Molecular Pattern Linked to Colon Cancer Prognosis

An international research team has identified a link between the expression patterns of a class of molecules called microRNAs and the progress of a patient's colon cancer. These data, the first to make such a link, may lead to a new tool for clinicians to help them assess the prognosis of a patient with colon cancer and decide on appropriate treatment, while potentially providing new developments in colon cancer therapies.

Scientific findings at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), Ohio State University, and the University of Hong Kong, China, were published in the January 30, 2008, issue of the Journal of the American Medical Association (JAMA). Additional research is planned to verify and build on these findings, which is needed before these results can be applied to tests or therapies in patients.

MicroRNAs are small pieces of RNA that regulate the transfer of information from genes into proteins. In particular, they are able to reduce or silence the expression of a particular gene by interfering with its messenger RNA, the molecular go-between that carries instructions from the gene to the cell's protein-building machinery.

"The association between gene regulation systems, particularly microRNAs, and cancer is becoming stronger all the time," said NCI Director John Niederhuber, MD. "These findings hold great promise for improving our ability to determine, at the time of diagnosis, what a patient's prognosis might be and the best course of therapy."

Genes for hundreds of microRNAs are contained within the human genome. Because they do not produce RNAs that encode proteins, their importance only has been recognized within the last decade, particularly in the context of cancer. MicroRNAs could potentially help to predict and lead to new drug development because their expression levels are altered in many types of tumors so they can be silenced with specifically designed inhibitors.

In this study, the research team, led by Curtis C. Harris, MD, chief of the Laboratory of Human Carcinogenesis at NCI's Center for Cancer Research, compared microRNA expression profiles in tumor and adjacent healthy tissues from two groups of patients with colon cancer. The groups were comprised of 84 patients in the United States and 113 in Hong Kong. Using genomic technologies, the researchers identified five microRNAs that were present in much greater amounts in colon cancer tumors than in normal tissues and were associated with disease progression. The strong association between one microRNA in particular, called miR-21, and poor survival in both the United States and Hong Kong patient groups suggested that it warranted further study.

Subsequently, the scientists found that miR-21 expression tracked tumor stage; the more advanced the tumor, the greater the amount of miR-21 present, indicating that it may play a role in cancer development and progression and could, therefore, serve as a good drug development target. Comparisons of tumor stage, miR-21 expression, and clinical outcome in patients with stage II or III colon cancer also revealed associations between high levels of miR-21 and poor survival, poor therapeutic outcome, and, in patients who experienced a disease relapse, more rapid recurrence.

"To the best of our knowledge, this is the largest study done so far comparing microRNA profiles and clinical outcomes in colon cancer, and the only one to use tissues and data from two independent groups," Harris noted. These data build both a rationale for using expression of these five microRNAs as a prognostic tool in colon cancer and lend weight to a role for miR-21 in colon cancer development and treatment."

Reference

Schetter, A.J., Leung, S.Y., Sohn, J.J., Zanetti, K.A., Bowman, E.D., Yanaihara, N., et al. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299(4), 425-436.

For more information about cancer, please visit the NCI Web site, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

The SIGs Virtual Community Keeps You Connected

Jenny Shinsky
Pittsburgh, PA
jshinsky@ons.org

The SIGs Virtual Community was developed to improve communication among SIG leaders and members. Visiting your SIG’s Web page on the Virtual Community keeps you updated about SIG activities by providing you with important information and resources.

To find your SIG’s page, visit the SIGs Virtual Community and select “Find a SIG” from the top navigation.

Many features in the SIGs Virtual Community are useful to all members. From your SIG’s main page, you can subscribe to SIG announcements, calendar events, and the discussion forum. Once you are subscribed to the areas, you will receive an e-mail every time an announcement, event, or discussion has been posted. Announcements pertaining to your SIG, such as scholarship, leadership, and meeting information, are added frequently.SIG events on the SIG calendar are showcased on the main page for your convenience. Simply click on an event for detailed information.

The About Us area features information about your SIG leaders. The News section provides important information, such as minutes from past meetings and newsletters. Educational news and photos also can be found here.

Click the Discussions button at the top of your SIG’s page to access the area. You can post a message, comment, or question and fellow SIG members can read your post and respond.

Check the ONS National Announcements section every month for updated information from ONS such as continuing nursing education offerings and events.

If you have questions or problems navigating the SIGs Virtual Community, contact Jenny Shinsky at jshinsky@ons.org.
 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

Putting Evidence Into Practice®
ONS PEP Resources Provide Quick Information on Evidence-Based Interventions

Margaretta S. Page, RN, MS, primary author of the ONS Putting Evidence Into Practice® (PEP) card on sleep-wake disturbances and its corresponding article in the Clinical Journal of Oncology Nursing (Vol. 10, No. 6, pp. 753–567), recounts her firsthand experience using the PEP resources. Click here for the article.
 
Back to SIG Newsletter front page
 

 
 

Special Interest Group Newsletter  June 2008
 
   

Membership Information

SIG Membership Benefits

  • Network with colleagues in an identified subspecialty area around the country.
  • Contribute articles for your SIG’s newsletter.
  • Participate in discussions with other SIG members.
  • Contribute to the future path of the SIG.
  • Share your expertise.
  • Support and/or mentor a colleague.
  • Receive information about the latest advancements in treatments, clinical trials, etc.
  • Participate in ONS leadership by running for SIG coordinator-elect or join SIG work groups.
  • Acquire information with a click of a mouse at http://ons.org/membership including
    • Educational opportunities for your subspecialty
    • Education material on practice
    • Calls to action
    • News impacting or affecting your specific SIG
    • Newsletters
    • Communiqués
    • Meeting minutes.

Join a Virtual Community

A great way to stay connected to your SIG is to join its Virtual Community. It’s easy to do so. All you will need to do is

  • Log on to the ONS Web site (http://www.ons.org/).
  • Select "Membership" from the tabs above.
  • Then, click on "ONS Chapters and Special Interest Groups."
  • Scroll down to "Visit the ONS Special Interest Groups (SIG) Virtual Community" and click.
  • Now, select "Find a SIG."
  • Locate and click on the name of your SIG from the list of all ONS SIGs displayed.
  • Once the front page of your SIG’s Virtual Community appears on screen, select "New User" from the top left. (This allows you to create log-in credentials.)
  • Type the required information into the text fields as prompted.
  • Click "Join Group" (at the bottom right of the text fields) when done.

    Special Notices


    • If you already have log-in credentials generated from the ONS Web site, use this information instead of attempting to generate new information.
    • If you created log-in credentials for the ONS Web site and wish to have different log-in information, you will not be able to use the same e-mail address to generate your new credentials. Instead, use an alternate e-mail address.

Subscribe to Your SIG’s Virtual Community Discussion Forum

All members are encouraged to participate in their SIG’s discussion forum. This area affords the opportunity for exchange of information between members and nonmembers on topics specific to all oncology subspecialties. Once you have your log-in credentials, you are ready to subscribe to your SIG’s Virtual Community discussion forum. To do so,

  • Select "Log In," located next to "New User," and enter your information.
  • Next, click on the "Discussion" tab on the top right of the title bar.
  • Now, select "Featured Discussion" from the left drop-down menu.
  • Locate and select "Subscribe to Discussion" inside the "Featured Discussion" section.
  • Go to "Subscription Options" and select "Options."
  • When you have selected and entered all required criteria, you will receive a confirmation message.
  • Click "Finish."
  • You are now ready to begin participating in your SIG’s discussion forum.

Participate in Your SIG’s Virtual Community Discussion Forum

  • First, log in. (This allows others to identify you and enables you to receive notification [via e-mail] each time a response or new topic is posted.)
  • Click on "Discussion" from the top title bar.
  • Select "Featured Discussion" from the left drop-down menu.
  • Click on any posted topic to view contents and post responses.

Sign Up to Receive Your SIG’s Virtual Community Announcements

As an added feature, members also are able to register to receive their SIG’s announcements by e-mail.

  • From your SIG’s Virtual Community page, locate the "Sign Up Here to Receive Your SIG’s Announcements" section. This appears above the posted announcements section.
  • Select the "Click Here" feature, which will take you to a link to subscribe.
  • Once the "For Announcement Subscription Only" page appears on select how you wish to receive your announcements.
    • As individual e-mails each time a new announcement is posted
    • One e-mail per day comprised of all new daily announcements posted
    • Opt-out, indicating that you will frequently browse your SIG’s Virtual Community page for new postings
  • Enter your e-mail address.
  • Click on "Next Page."
  • Because you have already joined your SIG’s Virtual Community, you will receive a security prompt with your registered user name already listed. Enter your password at this prompt and click "Finish."
  • This will bring up a listing of your SIG’s posted announcements. Click on "My SIG’s Page" to view all postings in their entirety or to conclude the registration process and begin browsing.
 
 
Back to SIG Newsletter front page
 
 
 

Special Interest Group Newsletter  June 2008
 
   

Cancer Genetics SIG Officers

Coordinator (2008-2010)
Lisa Aiello-Laws, RN, MSN, APN-C, APNG, AOCNS®
North Cape May, NJ
llaws@itapartners.com

Ex-Officio (2008-2009)
Jennifer T. Loud, RN, MSN, CRNP, DNP
Derwood, MD
loudj@mail.nih.gov

Editor
Millie Arnold, BS, RN, OCN®, CCRC
Mesquite, TX
mildreda@baylorhealth.edu

 

Co-Editor
Patricia Kelly, RN, MS, CNS, AOCN®
Dallas, TX
patriciakelly@texashealth.org

ONS Copy Editor
Emily Nalevanko, BA
Pittsburgh, PA
enalevanko@ons.org

Know someone who would like to receive a print copy of this newsletter?
To print a copy of this newsletter from your home or office computer, click here or on the printer icon located on the SIG Newsletter front page. Print copies of each online SIG newsletter also are available through the ONS National Office. To have a copy mailed to you or another SIG member, contact Membership/Leadership Administrative Assistant Carol DeMarco at cdemarco@ons.org or 866-257-4ONS, ext. 6230.

To view past newsletters, click here.

ONS Membership/Leadership Team Contact Information

Angie Stengel, MS, CAE, Director of Membership/Leadership
astengel@ons.org
412-859-6244

Diane Scheuring, MBA, CMP, Manager of Member Services
dscheuring@ons.org
412-859-6256

Carol DeMarco, Membership/Leadership Administrative Assistant
cdemarco@ons.org
412-859-6230

The Oncology Nursing Society (ONS) does not assume responsibility for the opinions expressed and information provided by authors or by Special Interest Groups (SIGs). Acceptance of advertising or corporate support does not indicate or imply endorsement of the company or its products by ONS or the SIG. Web sites listed in the SIG newsletters are provided for information only. Hosts are responsible for their own content and availability.

Oncology Nursing Society
125 Enterprise Dr.
Pittsburgh, PA 15275-1214
866-257-4ONS
412-859-6100
www.ons.org

 
 
Back to SIG Newsletter front page